10 results on '"Ibrahim, Tareq"'
Search Results
2. Do outcomes following intervention for drug-eluting stent restenosis depend on whether the restenosed stent was polymer-free or polymer-coated?
- Author
-
Harada, Yukinori, Schneider, Simon, Colleran, Roisin, Rai, Himanshu, Bohner, Janika, Kuna, Constantin, Kufner, Sebastian, Giacoppo, Daniele, Schüpke, Stefanie, Joner, Michael, Ibrahim, Tareq, Laugwitz, Karl-Ludwig, Kastrati, Adnan, and Byrne, Robert A.
- Abstract
Copyright of Revista Española de Cardiología (18855857) is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2020
- Full Text
- View/download PDF
3. Comparison of Vascular Closure Devices Versus Manual Compression After Femoral Artery Puncture in Women: Gender-Based Analysis of a Large Scale, Randomized Clinical Trial.
- Author
-
Gewalt, Senta M., Helde, Sandra M., Ibrahim, Tareq, Mayer, Katharina, Schmidt, Roland, Bott-Flügel, Lorenz, Hoppe, Katharina, Ott, Ilka, Hieber, Julia, Morath, Tanja, Byrne, Robert A., Kufner, Sebastian, Cassese, Salvatore, Hoppmann, Petra, Fusaro, Massimiliano, Schunkert, Heribert, Laugwitz, Karl-Ludwig, Kastrati, Adnan, and Schüpke, Stefanie
- Abstract
BACKGROUND: The value of vascular closure devices (VCD) in women undergoing transfemoral catheterization has not been sufficiently investigated. METHODS AND RESULTS: This is a sex-specific analysis of 1395 women enrolled in a large-scale, randomized, multicenter trial, in which patients undergoing transfemoral diagnostic coronary angiography were randomly assigned in a 1:1:1 ratio to arteriotomy closure with an intravascular VCD, extravascular VCD, or manual compression (MC). Primary objective was to assess the safety and efficacy of 2 different VCD compared with MC regarding vascular access-site complications at 30 days. A secondary comparison was between 2 different types of contemporary VCD. Overall, women were at higher risk for vascular access-site complications compared with men (9.0% versus 6.4%; P=0.002). Vascular access-site complications were comparable in women assigned to VCD and MC (8.6% versus 9.8%; P=0.451). There was no interaction of treatment effect and sex (P
interaction =0.970). Time to hemostasis was significantly shortened with VCD compared with MC (1 [interquartile range, 0.5-2.0] minutes) versus 11 [interquartile range, 10-15] minutes; P<0.001); however, more women with VCD required repeat MC (2.4% versus 0.6%; P=0.018). The use of the intravascular compared with the extravascular VCD was associated with a numerical reduction in vascular access-site complications (6.6% versus 10.7%; P=0.027) and significant reductions in time to hemostasis and VCD failure. CONCLUSIONS: In women undergoing diagnostic coronary angiography via the common femoral artery, VCD and MC provided comparable safety, while time to hemostasis was reduced with VCD. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
4. Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial.
- Author
-
Steppich, Birgit, Groha, Philip, Ibrahim, Tareq, Schunkert, Heribert, Laugwitz, Karl-Ludwig, Hadamitzky, Martin, Kastrati, Adnan, Ott, Ilka, and Regeneration of Vital Myocardium in ST-Segment Elevation Myocardial Infarction by Erythropoietin (REVIVAL-3) Study Investigators
- Subjects
ERYTHROPOIETIN ,ERYTHROPOIETIN receptors ,MYOCARDIAL infarction treatment ,CLINICAL trials ,MEDICAL practice ,THERAPEUTICS ,CARDIOVASCULAR system ,COMPARATIVE studies ,DOSE-effect relationship in pharmacology ,INTRAVENOUS injections ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL care ,MEDICAL cooperation ,POSTOPERATIVE care ,RECOMBINANT proteins ,RESEARCH ,STATISTICAL sampling ,SURVIVAL ,TIME ,EVALUATION research ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,BLIND experiment ,CORONARY angiography - Abstract
Background: Erythropoietin (EPO) has been suggested to promote cardiac repair after MI. However, the randomized, double-blind, placebo controlled REVIVAL-3 trial showed that short term high dose EPO in timely reperfused myocardium does not improve left ventricular ejection fraction after 6 months. Moreover, the study raised safety concerns due to a trend towards a higher incidence of adverse clinical events as well as a increase in neointima formation after treatment with EPO. The present study therefore aimed to assess the 5-year clinical outcomes.Methods: After successful reperfusion 138 patients with STEMI were randomly assigned to receive epoetin beta (3.33×104 U, n = 68) or placebo (n = 70) immediately, 24 and 48 h after percutaneous coronary intervention. The primary outcome of the present study- the combined incidence of MACE 5 years after randomization - occurred in 25% of the patients assigned to epoetin beta and 17% of the patients assigned to placebo (RR 1.5; 95% CI 0.8-3.5; p = 0.26). Target lesion revascularization was required in 15 patients (22.1%) treated with epoetin-ß and 9 patients (12.9%) treated with placebo (p = 0.15). Analysis of patients in the upper and lower quartile of baseline hemoglobin as an indirect estimate of endogenous erythropoietin levels revealed no significant impact of endogenous erythropoietin on efficiency of exogen administered epoetin-ß in terms of death and MACE.Conclusion: These long-term follow-up data show that epoetin beta does not improve clinical outcomes of patients with acute myocardial infarction.Trial Registration: URL www.clinicaltrials.gov ; Unique identifier NCT00390832; trial registration date October 19th 2006. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
5. Comparison of Vascular Closure Devices vs Manual Compression After Femoral Artery Puncture.
- Author
-
Schulz-Schüpke, Stefanie, Helde, Sandra, Gewalt, Senta, Ibrahim, Tareq, Linhardt, Maryam, Haas, Katharina, Hoppe, Katharina, Böttiger, Corinna, Groha, Philip, Bradaric, Christian, Schmidt, Roland, Bott-Flügel, Lorenz, Ott, Ilka, Goedel, Julia, Byrne, Robert A., Schneider, Simon, Burgdorf, Christof, Morath, Tanja, Kufner, Sebastian, and Joner, Michael
- Subjects
VASCULAR closure devices ,COMPRESSION therapy ,FEMORAL artery ,HEMOSTASIS ,CORONARY angiography ,CLINICAL trials ,WOUNDS & injuries - Abstract
IMPORTANCE The role of vascular closure devices (VCD) for the achievement of hemostasis in patients undergoing transfemoral coronary angiography remains controversial. OBJECTIVE To compare outcomes with the use of 2 hemostasis strategies after diagnostic coronary angiography performed via transfemoral access--a VCD-based strategy with 2 types of devices, an intravascular device and an extravascular device, vs standard manual compression. The primary hypothesis to be tested was that femoral hemostasis achieved through VCD is noninferior to manual compression in terms of vascular access--site complications. A secondary objective was the comparison of the 2 types of VCD. DESIGN, SETTING, AND PARTICIPANTS Randomized, large-scale, multicenter, open-label clinical trial. We enrolled 4524 patients undergoing coronary angiography with a 6 French sheath via the common femoral artery from April 2011 through May 2014 in 4 centers in Germany. Last 30-day follow-up was performed in July 2014. INTERVENTIONS After angiography of the access site, patients were randomized to hemostasis with an intravascular VCD, extravascular VCD, or manual compression in a 1:1:1 ratio. MAIN OUTCOMES AND MEASURES Primary end point: the composite of access site--related vascular complications at 30 days after randomization with a 2%noninferiority margin. Secondary end points: time to hemostasis, repeat manual compression, and VCD failure. An α-level of .025 was chosen for primary and secondary comparisons. RESULTS Of the 4524 enrolled patients, 3015 were randomly assigned to a VCD group (1509 received intravascular VCD and 1506 received extravascular VCD) and 1509 patients were randomly assigned to the manual compression group. Before hospital discharge, duplex sonography of the access site was performed in 4231 (94%) patients. The primary end point was observed in 208 patients (6.9%) assigned to receive a VCD and 119 patients (7.9%) assigned to manual compression (difference, --1.0% [1-sided 97.5%CI, 0.7%]; P for noninferiority <.001). Time to hemostasis was significantly shorter in patients with VCD (1 minute [interquartile range {IQR}, 0.5-2.0]), vs manual compression (10 minutes [IQR, 10-15]; P < .001). Time to hemostasis was significantly shorter among patients with intravascular VCD (0.5 minute [IQR, 0.2-1.0]), vs extravascular VCD (2.0 minutes [IQR, 1.0-2.0]; P <.001) and closure device failure was also significantly lower among those with intravascular vs extravascular VCD (80 patients [5.3%], vs 184 patients [12.2%]; P < .001). CONCLUSIONS AND RELEVANCE In patients undergoing transfemoral coronary angiography, VCDs were noninferior to manual compression in terms of vascular access-site complications and reduced time to hemostasis. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
6. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography.
- Author
-
Cassese, Salvatore, Byrne, Robert A., Tomohisa Tada, Pinieck, Susanne, Joner, Michael, Ibrahim, Tareq, King, Lamin A., Fusaro, Massimiliano, Laugwitz, Karl-Ludwig, and Kastrati, Adnan
- Subjects
DISEASE incidence ,CORONARY restenosis ,CORONARY angiography ,METALS in medicine ,DRUG-eluting stents ,FOLLOW-up studies (Medicine) - Abstract
Objective Systematic investigation of restenosis after percutaneous coronary intervention (PCI) with bare metal stents (BMS) or first or second generation drug eluting stents (DES) in large scale, broadly inclusive patient populations undergoing follow-up angiography represents a gap in our scientific knowledge. We investigated the incidence of angiographically proven restenosis and its predictors in patients undergoing PCI with stents. Methods All patients undergoing successful implantation of coronary stents for de novo lesions from 1998 to 2009 and follow-up angiography at 6-8 months at two centres in Munich, Germany were eligible for inclusion. Patients with cardiogenic shock, dialysis dependent renal insufficiency or previous cardiac transplantation were excluded. Data were prospectively collected. The incidence of restenosis, defined as diameter stenosis ≥50% in the in-segment area at follow-up angiography, and its predictors were evaluated. Results A total of 12 094 patients met inclusion criteria. Angiographic follow-up was available for 10 004 patients (77.5%) with 15 004 treated lesions. Binary restenosis was detected in 2643 (26.4%) patients. Use of first generation DES versus BMS (OR 0.35, 95% CI 0.31 to 0.39) and second generation DES versus first generation DES (OR 0.67, 95% CI 0.58 to 0.77) were independent predictors of lower rates of restenosis. At multivariate analysis, smaller vessel size (OR 1.59, 95% CI 1.52 to 1.68, for each 0.5 mm decrease), total stented length (OR 1.27, 95% CI 1.21 to 1.33, for each 10 mm increase), complex lesion morphology (OR 1.35, 95% 1.21 to 1.51), presence of diabetes mellitus (OR 1.32, 95% 1.19 to 1.46), and history of bypass surgery (OR 1.38, 95% CI 1.20 to 1.58) were independently associated with restenosis and were similar across the spectrum of stent devices. Conclusions In this large cohort of patients with angiographic surveillance we demonstrated the impact of device development on antirestenotic efficacy, with sequentially improved efficacy from BMS to first generation DES to second generation DES. Predictors of restenosis were small vessel size, increased stented length, complex lesion morphology, diabetes mellitus, and prior bypass surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
7. 10-Year Outcomes From a Randomized Trial of Polymer-Free Versus Durable Polymer Drug-Eluting Coronary Stents.
- Author
-
Kufner, Sebastian, Ernst, Maximilian, Cassese, Salvatore, Joner, Michael, Mayer, Katharina, Colleran, Roisin, Koppara, Tobias, Xhepa, Erion, Koch, Tobias, Wiebe, Jens, Ibrahim, Tareq, Fusaro, Massimiliano, Laugwitz, Karl-Ludwig, Schunkert, Heribert, Kastrati, Adnan, Byrne, Robert A, and ISAR-TEST-5 Investigators
- Subjects
- *
CORONARY artery surgery , *PROSTHETICS , *RESEARCH , *RAPAMYCIN , *DRUG-eluting stents , *RESEARCH methodology , *RETROSPECTIVE studies , *EVALUATION research , *MEDICAL cooperation , *CORONARY angiography , *TREATMENT effectiveness , *COMPARATIVE studies , *CORONARY artery disease , *FORECASTING , *POLYMERS , *CORONARY arteries , *LONGITUDINAL method , *PHARMACODYNAMICS - Abstract
Background: Outcome data after extended long-term follow-up of patients with coronary artery disease treated with drug-eluting stents (DES) in randomized clinical trials are scant.Objectives: Performance differences among devices may be expected to emerge over time depending on whether stenting is done with polymer-free or durable polymer DES. This study assessed the 10-year outcomes of patients enrolled in the ISAR-TEST-5 (Test Efficacy of Sirolimus- and Probucol-Eluting Versus Zotarolimus-Eluting Stents) trial.Methods: A total of 3,002 patients were randomized to treatment with either polymer-free sirolimus- and probucol-eluting stents (n = 2,002) or durable polymer zotarolimus-eluting stents (n = 1,000). The primary endpoint was the composite of cardiac death, target vessel-related myocardial infarction, or target lesion revascularization (a device-oriented composite endpoint [DOCE]). Additional endpoints of interest were the patient-oriented composite endpoint (POCE), including all-cause death, any myocardial infarction, or any revascularization; individual components of the composite endpoints; and definite or probable stent thrombosis.Results: The median age of the patients at randomization was 67.8 years. At 10 years, 63.9% of patients were alive. The rates of DOCE and POCE were high in both groups with no difference in the incidence between polymer-free sirolimus- and probucol-eluting stents and durable polymer zotarolimus-eluting stents (DOCE: 43.8% vs. 43.0%, respectively; hazard ratio: 1.01; 95% confidence interval [CI]: 0.89 to 1.14; p = 0.90; POCE: 66.2% vs. 67.7%, respectively; hazard ratio: 0.94; 95% CI: 0.86 to 1.04; p = 0.22). The rates of the individual components of the composite endpoints were comparable in both groups. The incidence of definite/probable stent thrombosis over 10 years was low and comparable in both groups (1.6% vs. 1.9%; hazard ratio: 0.85; 95% CI: 0.46 to 1.54; p = 0.58).Conclusions: At 10 years, there were no measurable differences in outcomes between patients treated with polymer-free versus durable polymer DES. The incidence of stent thrombosis was low and comparable in both groups. High overall adverse clinical event rates were observed during extended follow-up. (Test Efficacy of Sirolimus- and Probucol-Eluting Versus Zotarolimus-Eluting Stents [ISAR-TEST-5]; NCT00598533). [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
8. Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease.
- Author
-
ISAR-TEST 4 (Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents) Investigators, Kufner, Sebastian, Thannheimer, Anna, Mayer, Katharina, Cassese, Salvatore, Joner, Michael, Schunkert, Heribert, Kastrati, Adnan, Byrne, Robert A., Hoppmann, Petra, Ibrahim, Tareq, Laugwitz, Karl-Ludwig, and Byrne, Robert
- Subjects
- *
DRUG-eluting stents , *CORONARY disease , *CLINICAL trial registries , *MYOCARDIAL infarction , *POLYMERS , *SURFACE coatings , *MEDICAL equipment , *CARDIOVASCULAR agents , *CARDIOVASCULAR system , *CORONARY artery stenosis , *MEDICAL care , *PROSTHETICS , *RISK assessment , *STATISTICAL sampling , *TIME , *RAPAMYCIN , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *CORONARY angiography ,MYOCARDIAL infarction-related mortality - Abstract
Background: New-generation drug-eluting stents offer the potential for enhanced late outcomes in comparison with early generation drug-eluting stents. However, assessment of extended long-term outcomes for these devices is lacking, especially regarding the comparison between new-generation drug-eluting stents with biodegradable or permanent polymers. The aim of this study is to compare the efficacy and safety of biodegradable polymer-based sirolimus-eluting stents (BP-SES; Yukon Choice PC) versus permanent polymer-based everolimus-eluting stents (PP-EES; Xience) versus early generation permanent polymer-based sirolimus-eluting stents (PP-SES; Cypher) at 10-year follow-up.Methods: Overall, 2603 patients were randomized to treatment with BP-SES (n=1299), PP-EES (n=652), or PP-SES (n=652). The primary end point of this analysis was major adverse cardiac event, the composite of death, myocardial infarction, or target lesion revascularization. The main secondary end point of interest was definite/probable stent thrombosis. Follow-up at 10 years was available in 83% of the study patients.Results: The 10-year incidence of major adverse cardiac event (BP-SES 47.7% versus PP-EES 46.0% versus PP-SES 54.9%, P=0.003) and mortality (BP-SES 31.8% versus PP-EES 30.3% versus PP-SES 37.2%, P=0.02) was different among the groups. Definite/probable stent thrombosis was not significantly different among the groups (BP-SES 1.8% versus PP-EES 2.5% versus PP-SES 3.7%, P=0.09). Definite stent thrombosis was significantly different among the groups (BP-SES 1.1% versus PP-EES 0.8% versus PP-SES 2.4%, P=0.03). There were no significant differences between BP-SES and PP-EES.Conclusions: In this unique long-term outcome analysis, BP-SES and PP-EES showed comparable clinical outcomes out to 10 years. PP-SES had higher rates of major adverse cardiac events and definite stent thrombosis.Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00598676. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
9. TCT-483 Angiographic and two-year clinical outcomes following percutaneous coronary intervention for in-stent restenosis of polymer-free sirolimus- and probucol-eluting stent compared with durable polymer zotarolimus-eluting stent.
- Author
-
Harada, Yukinori, Colleran, Roisin, Kufner, Sebastian, Giacoppo, Daniele, Rheude, Tobias, Michel, Jonathan, Wiebe, Jens, Cassese, Salvatore, Ibrahim, Tareq, Laugwitz, Karl-Ludwig, Kastrati, Adnan, and Byrne, Robert
- Subjects
- *
CORONARY restenosis , *CORONARY angiography , *PERCUTANEOUS coronary intervention , *RAPAMYCIN , *MEDICAL polymers , *SURGICAL stents , *DRUG-eluting stents , *THERAPEUTICS - Published
- 2016
- Full Text
- View/download PDF
10. TCT-399 Impact of post-dilatation on angiographic and clinical outcomes of patients undergoing bioresorbable scaffold implantation in clinical practice.
- Author
-
Wiebe, Jens, Harada, Yukinori, Hoppmann, Petra, Colleran, Roisin, Kufner, Sebastian, Cassese, Salvatore, Xhepa, Erion, Rheude, Tobias, Giacoppo, Daniele, Ibrahim, Tareq, Laugwitz, Karl-Ludwig, Kastrati, Adnan, and Byrne, Robert
- Subjects
- *
HEART dilatation , *CORONARY angiography , *MEDICAL practice , *TISSUE scaffolds , *CARDIAC patients - Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.